Stocks · News reference
HSBC analyst Rajesh Kumar maintains Eli Lilly (NYSE:LLY) with a Reduce and raises the price target from $850 to $940.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.
Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.
The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.